Orion Corporation

Orion Oyj
Type	Julkinen osakeyhtiö
Traded as	Nasdaq Helsinki: ORNBV
Industry	Pharmaceutical industry
Founded	1917
Headquarters	Espoo, Finland
Key people	Timo Lappalainen (President and CEO), Hannu Syrjänen (Chairman)
Products	Pharmaceuticals, active pharmaceutical ingredients and diagnostic tests
Revenue	€1.074 billion (2016)
Operating income	€315 million (2016)
Net income	€249 million (2016)
Total assets	€1.063 billion (2016)
Total equity	€641 million (2016)
Number of employees	3,446 (2016)
Website	www.orion.fi
	Footnotes / references; [1]

Orion Corporation, founded in 1917 and headquartered at Espoo, Finland, is a Finnish company, which develops, manufactures and markets pharmaceuticals, active pharmaceutical ingredients and diagnostic tests for global markets. The company also has a large R&D unit in Turku.

Orion's class A and B shares are listed on the Helsinki Stock Exchange.

Products

Analgesics

Indalgin (indometacin, ethylmorphine)
Dexdor (dexmedetomidine)
Para-Tabs (paracetamol)
Generic drug of pregabalin

NSAIDs

Burana (ibuprofen)
Ketorin (ketoprofen)
Pronaxen (naproxen)

Anti-diabetic drugs

Glimepirid Orion (glimepiride)
Metforem (metformin)
Origlucon (glibenclamide)

Gastric acid related drugs

Ranimex (ranitidine)
Zolt (lansoprazole)

Oral hygiene

Daktarin (miconazole)
Elmex (olaflur)

Motion sickness drugs

Vertipam (cyclizine, diazepam and nicotinic acid)

Vitamins

Cohemin (cyanocobalamin)
Neuramin (thiamine)

Anticoagulants

Marevan (warfarin)

Cardiovascular drugs

Digoxin (digoxin)
Disomet (disopyramide)
Dopmin (dopamine)
Kiniduron (quinidine)
Lidocard (lidocaine)
Nitro (glyceryl trinitrate)
Nitrosid (isosorbide dinitrate)
Ormox (isosorbide mononitrate)

Antihypertensive drugs

Amlodipin Orion (amlodipine)
Carvedilol Orion Pharma (carvedilol)
Dilzem (diltiazem)
Escor (nilvadipine)
Espesil (acebutolol)
Lisipril (lisinopril)
Lopril (captopril)
Nifangin (nifedipine)
Orloc (bisoprolol)
Pinloc (pindolol)
Pratsiol (prazosin)
Propral (propranolol)
Selopral (metoprolol)
Verpamil (verapamil)
Lisipril Comp (lisinopril and hydrochlorothiazide)
Orloc Comp (bisoprolol and hydrochlorothiazide)

Inotropic drugs

Simdax (levosimendan)

Diuretics

Diurex (hydrochlorothiazide and amiloride)
Furesis (furosemide)
Furesis Comp (furosemide and triamterene)
Hydrex (hydrochlorothiazide)
Indapamide Orion (indapamide)
Spiresis (spironolactone)
Uretren Comp (trichlormethiazide and triamterene)

Hypolipidemic agents

Atorvastatin Orion (atorvastatin)
Lovacol (lovastatin)
Pravastatin Orion (pravastatin)
Simvastatin Orion (simvastatin)

References

↑ https://www.orion.fi/globalassets/documents/orion-group/investors/annual-reports/orion-financial-statement-documents-2016.pdf

External links

Official website

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] ttps://www.orion.fi/globalassets/documents/orion-group/investors/annual-reports/orion-financial-statement-documents-2016.pdf